Oral rigosertib as a single agent demonstrates activity in a Phase 2 trial for lower-risk MDS 32% of 62 evaluable patients, and 44% of patients receiving optimal dosing, achieved transfusion independence New data on the molecular basis of the combination therapy with rigosertib and azacitidine in
NEWTOWN, Pa. , Nov. 20, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), will present at the LD Micro
Novel formulation of rigosertib with enhanced bioavailability and stability Liver microsomal stability of ON 123300, a first-in-class dual inhibitor of CDK4/6 + ARK5 Formulation approaches to augment bioavailability of ON 123300 NEWTOWN, Pa. , Nov. 16, 2017 (GLOBE NEWSWIRE) -- Onconova
Rigosertib reduced or stabilized bone marrow blasts and improved peripheral blood counts Patients with response or stable disease had one year longer survival than non-responders Rigosertib was well tolerated and a recommended dose for further evaluation was established NEWTOWN, Pa. , Nov.
NEWTOWN, Pa. , Nov. 10, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS) today announced that it
NEWTOWN, Pa. , Nov. 09, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer, with a primary focus on Myelodysplastic Syndromes (MDS), today provided a
Company to Hold Conference Call and Webcast at 9:00 a.m. Eastern Time on Thursday, November 9, 2017 NEWTOWN, Pa. , Nov. 02, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat
NEWTOWN, Pa. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that two abstracts relating to the Company's lead product candidate,
NEWTOWN, Pa. , Oct. 10, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), announced that they will present and
NEWTOWN, Pa. , Oct. 04, 2017 (GLOBE NEWSWIRE) -- Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, with a primary focus on myelodysplastic syndromes (MDS), today announced that it will host a